Profile data is unavailable for this security.
About the company
Ikena Oncology, Inc. is a clinical-stage, targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. Its lead program in the RAS pathway, IK-595, is a molecular glue designed to trap MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors. IK-595’s ability to complex the RAFs, including CRAF prevents a signaling bypass mechanism that cancer cells employ to drive therapeutic resistance to other drugs in this class. IK-595 is being developed as an oral therapy and evaluated in a Phase I clinical trial in RAS and RAF mutant cancers.
- Revenue in USD (TTM)0.00
- Net income in USD-41.71m
- Incorporated2016
- Employees9.00
- LocationIkena Oncology Inc645 Summer Street, Suite 101BOSTON 02210United StatesUSA
- Phone+1 (857) 273-8343
- Fax+1 (302) 655-5049
- Websitehttps://www.ikenaoncology.com
More ▼
Mergers & acquisitions
| Acquired company | IKNA:NMQ since announced | Transaction value |
|---|---|---|
| Inmagene Biopharmaceuticals | -18.06% | -- |
Data delayed at least 15 minutes, as of Jul 18 2025 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jupiter Neurosciences Inc | 0.00 | -3.33m | 56.94m | 4.00 | -- | 18.58 | -- | -- | -0.104 | -0.104 | 0.00 | 0.0926 | -- | -- | -- | 0.00 | -- | -383.24 | -- | -- | -- | -- | -- | -902.90 | -- | -20.74 | 0.0456 | -- | -- | -- | 49.00 | -- | -- | -- |
| Vicapsys Life Sciences Inc | 0.00 | -1.35m | 57.30m | 2.00 | -- | -- | -- | -- | -0.0396 | -0.0396 | 0.00 | -0.0817 | 0.00 | -- | -- | 0.00 | -904.16 | -- | -- | -- | -- | -- | -- | -- | -- | -7.46 | -- | -- | -- | -- | -19.61 | -- | -- | -- |
| Propanc Biopharma Inc | 0.00 | -55.21m | 57.94m | 1.00 | -- | 3.20 | -- | -- | -168.14 | -168.14 | 0.00 | 1.56 | 0.00 | -- | -- | -- | -489.35 | -- | -759.66 | -- | -- | -- | -- | -- | -- | -106.70 | 0.0644 | -- | -- | -- | 35.61 | -- | -- | -- |
| Adverum Biotechnologies Inc | 1.00m | -150.80m | 59.33m | 155.00 | -- | 2.23 | -- | 59.33 | -7.22 | -7.22 | 0.0479 | 1.27 | 0.0049 | -- | -- | 6,451.61 | -74.38 | -42.24 | -84.05 | -45.55 | -- | -- | -15,079.90 | -5,542.36 | -- | -- | 0.00 | -- | -72.22 | 31.95 | -7.22 | -- | -54.20 | -- |
| Unicycive Therapeutics Inc | 0.00 | -22.07m | 59.37m | 22.00 | -- | 4.94 | -- | -- | -2.13 | -2.13 | 0.00 | 0.9412 | 0.00 | -- | -- | 0.00 | -37.83 | -188.44 | -91.06 | -723.53 | -- | -- | -- | -6,003.20 | -- | -- | 0.00 | -- | -100.00 | -- | -20.42 | -- | -- | -- |
| INmune Bio Inc | 50.00k | -40.80m | 59.55m | 22.00 | -- | 1.73 | -- | 1,191.02 | -1.95 | -1.95 | 0.0024 | 1.29 | 0.0012 | -- | 0.0244 | 2,272.73 | -96.41 | -45.54 | -137.69 | -52.16 | -- | -- | -81,592.00 | -19,298.45 | -- | -96.12 | 0.00 | -- | -90.97 | -- | -40.24 | -- | -- | -- |
| ABVC Biopharma Inc | 508.39k | -1.81m | 60.05m | 16.00 | -- | 10.19 | -- | 118.11 | -0.1434 | -0.1434 | 0.0392 | 0.3514 | 0.0347 | -- | 0.7076 | 31,774.38 | -15.15 | -105.17 | -32.38 | -217.00 | 99.90 | 75.19 | -437.11 | -2,124.21 | 0.2166 | -2.44 | 0.1706 | -- | 234.31 | -6.20 | 37.05 | -- | -- | -- |
| Medicinova Inc | 0.00 | -11.16m | 60.33m | 13.00 | -- | 1.21 | -- | -- | -0.2275 | -0.2275 | 0.00 | 1.02 | 0.00 | -- | -- | 0.00 | -19.35 | -15.56 | -20.16 | -16.17 | -- | -- | -- | -1,144.98 | -- | -- | 0.00 | -- | -100.00 | -- | -28.91 | -- | -39.68 | -- |
| Inotiv Inc | 480.40m | -87.47m | 60.80m | 1.98k | -- | 0.3855 | -- | 0.1266 | -3.18 | -3.18 | 16.98 | 4.59 | 0.6076 | 9.00 | 7.03 | 242,995.50 | -11.06 | -20.84 | -17.98 | -25.17 | 21.87 | 27.38 | -18.21 | -30.94 | 1.18 | -1.03 | 0.7184 | -- | -14.27 | 62.27 | -3.14 | -- | 26.53 | -- |
| Ikena Oncology Inc | 0.00 | -41.71m | 60.81m | 9.00 | -- | 0.5142 | -- | -- | -0.8643 | -0.8643 | 0.00 | 2.45 | 0.00 | -- | -- | 0.00 | -27.47 | -29.58 | -29.30 | -33.67 | -- | -- | -- | -407.25 | -- | -- | 0.00 | -- | -100.00 | -- | 27.77 | -- | -- | -- |
| Avalo Therapeutics Inc | 441.00k | -21.10m | 61.28m | 23.00 | 0.2583 | 0.4998 | 0.8363 | 138.97 | 21.91 | 21.91 | 0.0496 | 11.32 | 0.0034 | -- | -- | 19,173.91 | 55.68 | -94.60 | 356.71 | -128.31 | 164.85 | 81.11 | 16,556.01 | -790.66 | -- | -- | 0.00 | -- | -77.08 | -42.05 | -11.37 | -- | -- | -- |
| Werewolf Therapeutics Inc | 1.14m | -72.41m | 62.82m | 46.00 | -- | 1.10 | -- | 54.96 | -1.64 | -1.64 | 0.0259 | 1.28 | 0.008 | -- | -- | 24,847.83 | -50.84 | -33.10 | -57.48 | -36.81 | -- | -- | -6,335.17 | -593.05 | -- | -- | 0.3169 | -- | -90.55 | -- | -88.70 | -- | -0.919 | -- |
| Artiva Biotherapeutics Inc | 0.00 | -71.72m | 63.10m | 96.00 | -- | 0.3739 | -- | -- | -3.19 | -3.19 | 0.00 | 6.93 | 0.00 | -- | -- | 0.00 | -50.97 | -44.57 | -55.41 | -51.09 | -- | -- | -- | -596.66 | -- | -- | 0.0008 | -- | -99.25 | -- | -127.62 | -- | 18.74 | -- |
| Cue Biopharma Inc | 7.99m | -40.58m | 63.29m | 41.00 | -- | 7.89 | -- | 7.92 | -0.6644 | -0.6644 | 0.1278 | 0.1064 | 0.2097 | -- | 11.42 | 194,902.40 | -106.51 | -60.20 | -190.46 | -73.56 | -- | -- | -507.87 | -683.99 | -- | -- | 0.339 | -- | 69.16 | 21.84 | 19.83 | -- | 7.32 | -- |
Data as of Jul 18 2025. Currency figures normalised to Ikena Oncology Inc's reporting currency: US Dollar USD
37.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BML Capital Management LLCas of 16 Jun 2025 | 4.03m | 9.62% |
| BVF Partners LPas of 31 Mar 2025 | 4.01m | 9.57% |
| Deep Track Capital LPas of 31 Mar 2025 | 2.52m | 6.01% |
| OrbiMed Advisors LLCas of 30 Apr 2025 | 1.63m | 3.88% |
| The Vanguard Group, Inc.as of 31 Mar 2025 | 1.38m | 3.29% |
| Adage Capital Management LPas of 31 Mar 2025 | 800.00k | 1.91% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 345.36k | 0.82% |
| Geode Capital Management LLCas of 31 Mar 2025 | 317.09k | 0.76% |
| Peapod Lane Capital LLCas of 31 Mar 2025 | 296.44k | 0.71% |
| Renaissance Technologies LLCas of 31 Mar 2025 | 294.49k | 0.70% |
More ▼
Data from 31 Mar 2025 - 30 Apr 2025Source: FactSet Research Systems Inc.
